Ex vivo molecular rejuvenation improves the therapeutic activity of senescent human cardiac stem cells in a mouse model of myocardial infarction

Stem Cells

Volumn 32, Issue 9, 2014, Pages 2373-2385

  Avolio, Elisa ^a   Gianfranceschi, Giuseppe ^a   Cesselli, Daniela ^a   Caragnano, Angela ^a   Athanasakis, Emmanouil ^a   Katare, Rajesh ^b   Meloni, Marco ^b   Palma, Anita ^a   Barchiesi, Arianna ^a   Vascotto, Carlo ^a   Toffoletto, Barbara ^a   Mazzega, Elisa ^a   Finato, Nicoletta ^a   Aresu, Giuseppe ^a   Livi, Ugolino ^a   Emanueli, Costanza ^b   Scoles, Giacinto ^a   Beltrami, Carlo Alberto ^a   Madeddu, Paolo ^b   Beltrami, Antonio Paolo ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cellular senescence; Heart failure; Myocardial infarction; Stem cells

Indexed keywords

ADENOSINE PHOSPHATE; CYCLIC AMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; RAPAMYCIN; RESVERATROL; STILBENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CARDIAC STEM CELL; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REJUVENATION; SENESCENCE; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION; ANIMAL; CELL AGING; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HEART MUSCLE; METABOLISM; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; SCID MOUSE; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ANIMALS; CELL AGING; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, SCID; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; SIROLIMUS; STEM CELL TRANSPLANTATION; STILBENES;

EID: 84906275800     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1728     Document Type: Article

References (58)

1. Lawless C, Wang C, Jurk D, et al. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010; 45: 772-778.
2. Baker DJ, Sedivy JM,. Probing the depths of cellular senescence. J Cell Biol 2013; 202: 11-13.
3. Beltrami AP, Cesselli D, Beltrami CA,. At the stem of youth and health. Pharmacol Ther 2011; 129: 3-20.
4. Beltrami AP, Cesselli D, Beltrami CA,. Stem cell senescence and regenerative paradigms. Clin Pharmacol Ther 2012; 91: 21-29.
5. Cesselli D, Beltrami AP, D'Aurizio F, et al. Effects of age and heart failure on human cardiac stem cell function. Am J Pathol 2011; 179: 349-366.
6. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011; 378: 1847-1857.
7. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
8. Cottage CT, Bailey B, Fischer KM, et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res 2010; 106: 891-901.
9. Katare R, Oikawa A, Cesselli D, et al. Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res 2013; 97: 55-65.
10. Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013; 15: 978-990.
11. Pope RM, Tschopp J,. The role of interleukin-1 and the inflammasome in gout: Implications for therapy. Arthritis Rheum 2007; 56: 3183-3188.
12. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
13. Salminen A, Kaarniranta K,. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev 2012; 11: 230-241.
14. Laplante M, Sabatini DM,. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
15. Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440-455.
16. Korotchkina LG, Leontieva OV, Bukreeva EI, et al. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2: 344-352.
17. Gan B, DePinho RA,. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 2009; 8: 1003-1006.
18. Huang J, Manning BD,. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37 (Pt 1): 217-222.
19. Zoncu R, Efeyan A, Sabatini DM,. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
20. Thomson DM, Herway ST, Fillmore N, et al. AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J Appl Physiol (1985) 2008; 104: 429-438.
21. Hansen RT, 3rd, Zhang HT,. Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline. Brain Res 2013; 1516: 93-109.
22. Fusco S, Ripoli C, Podda MV, et al. A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction. Proc Natl Acad Sci USA 2012; 109: 621-626.
23. Noriega LG, Feige JN, Canto C, et al. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep 2011; 12: 1069-1076.
24. Alvarez-Saavedra M, Antoun G, Yanagiya A, et al. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet 2011; 20: 731-751.
25. Blagosklonny MV,. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: Terminology for TOR-driven aging. Aging (Albany NY) 2012; 4: 159-165.
26. Li H, Xia N, Forstermann U,. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012; 26: 102-110.
27. Demidenko ZN, Blagosklonny MV,. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009; 8: 1901-1904.
28. Xia L, Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008; 155: 387-394.
29. Penumathsa SV, Thirunavukkarasu M, Zhan L, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008; 12: 2350-2361.
30. Dasgupta B, Milbrandt J,. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104: 7217-7222.
31. Cesselli D, D'Aurizio F, Marcon P, et al. Cardiac stem cell senescence. Methods Mol Biol 2013; 976: 81-97.
32. Katare R, Riu F, Mitchell K, et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res 2011; 109: 894-906.
33. Scheidereit C,. IkappaB kinase complexes: Gateways to NF-kappaB activation and transcription. Oncogene 2006; 25: 6685-6705.
34. McMillan DH, Woeller CF, Thatcher TH, et al. Attenuation of inflammatory mediator production by the NF-kappaB member RelB is mediated by microRNA-146a in lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2013; 304: L774-781.
35. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123: 2143-2154.
36. Du K, Montminy M,. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998; 273: 32377-32379.
37. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107: 913-922.
38. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation 2013; 128: 1910-1923.
39. Coppe JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu Rev Pathol 2010; 5: 99-118.
40. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62: 194-204.
41. Gratia S, Kay L, Potenza L, et al. Inhibition of AMPK signalling by doxorubicin: At the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res 2012; 95: 290-299.
42. Dolinsky VW, Chan AY, Robillard Frayne I, et al. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009; 119: 1643-1652.
43. Johnson SC, Rabinovitch PS, Kaeberlein M,. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-345.
44. Chin JH, Okazaki M, Frazier JS, et al. Impaired cAMP-mediated gene expression and decreased cAMP response element binding protein in senescent cells. Am J Physiol 1996; 271 (1 Pt 1): C362-371.
45. Kunieda T, Minamino T, Katsuno T, et al. Cellular senescence impairs circadian expression of clock genes in vitro and in vivo. Circ Res 2006; 98: 532-539.
46. Habib SL,. Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells. Oncotarget 2011; 2: 958-959.
47. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148: 421-433.
48. Vaughan S, Jat PS,. Deciphering the role of nuclear factor-kappaB in cellular senescence. Aging (Albany NY) 2011; 3: 913-919.
49. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105: 1371-1377 e1.
50. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013; 111: 1394-1400.
51. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One 2012; 7: e33438.
52. Rodier F, Campisi J,. Four faces of cellular senescence. J Cell Biol 2011; 192: 547-556.
53. Naftali-Shani N, Itzhaki-Alfia A, Landa-Rouben N, et al. The origin of human mesenchymal stromal cells dictates their reparative properties. J Am Heart Assoc 2013; 2: e000253.
54. Wang X, Takagawa J, Lam VC, et al. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med 2011; 3: 100ra90.
55. Barile L, Lionetti V,. Prometheus's heart: What lies beneath. J Cell Mol Med 2012; 16: 228-236.
56. Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail 2014; 2: 49-61.
57. Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells. Circulation 2009; 120: 2559-2566.
58. Mohsin S, Khan M, Nguyen J, et al. Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ Res 2013; 113: 1169-1179.